在癌症治疗中使用的多 (ADP-Ribose) 聚合酶 (PARP) 抑制剂:进展,挑战和未来方向
Denys Bondar1, Yevgen Karpichev1
1Department of Chemistry and Biotechnology, Tallinn University of Technology (TalTech), Akadeemia tee 15, 12618 Tallinn, Estonia.
Biomolecules
|October 26, 2024
概括
聚基聚合酶 (PARP) 是DNA修复和癌症中的关键蛋白质. PARP 抑制剂作为抗癌药物表现有前途,新一代药物提供了更好的疗效和合成方法.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- 聚基聚合酶 (PARP) 是重要的核蛋白,参与DNA修复,转录和细胞死亡.
- 最丰富的PARP是PARP1,其功能是DNA损伤传感器,是癌症治疗的重要目标.
- 在黑色素瘤,肺癌和乳腺癌等瘤中增加PARP表达与预后不佳和治疗耐药性相关.
研究的目的:
- 审查PARP抑制剂的特性,发展和治疗机制.
- 讨论从第一代PARP抑制剂到第三代PARP抑制剂的进展.
- 探索新型抗癌剂的可持续合成方法和绿色化学方法.
主要方法:
- 关于PARP抑制剂的特性和发展的文献综述.
- 分析治疗机制和潜在的非目标应用.
- 讨论合成策略,包括绿色化学.
主要成果:
- PARP 抑制剂,特别是第三代化合物,作为单一疗法和与化疗和放射疗法结合的疗效被证明是有效的.
- 目前正在进行的II期临床试验强调了先进的PARP抑制剂的治疗潜力.
- 可持续的合成方法对于发现针对PARP的新抗癌剂至关重要.
结论:
- PARP 抑制剂代表了一类有前途的抗癌药物,具有不断发展的治疗策略.
- 对新型合成方法和向策略的进一步研究可以提高它们的临床实用性.
- 绿色化学原则为开发下一代PARP向癌症治疗提供了可持续的途径.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Long-patch Base Excision Repair
7.0K
Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
7.0K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Restarting Stalled Replication Forks
5.8K
DNA replication is initiated at sites containing predefined DNA sequences known as origins of replication. DNA is unwound at these sites by the minichromosome maintenance (MCM) helicase and other factors such as Cdc45 and the associated GINS complex.The unwound single strands are protected by replication protein A (RPA) until DNA polymerase starts synthesizing DNA at the 5’ end of the strand in the same direction as the replication fork. To prevent the replication fork from falling apart,...
5.8K
piRNA - Piwi-interacting RNAs
6.8K
PIWI-interacting RNAs, or piRNAs, are the most abundant short non-coding RNAs. More than 20,000 genes have been found in humans that code for piRNAs while only 2000 genes have been found for miRNAs. piRNAs can act at the transcriptional and post-transcriptional levels and have a vital role in silencing transposable elements present in germ cells. They are also involved in epigenetic silencing and activation. Previously, they were thought to function only in germ cells but new evidence suggests...
6.8K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K


